Form 483

Innovita, LLC Form 483, 2012-11-15

FDA issued a Form 483 to Innovita, LLC on 2012-11-15 with 9 public-safe observations.

483· Form 483 issued9 observations

Innovita, LLC · Ogden, United States · Issued November 15, 2012

Overview

  • 9 public-safe observations are available for this inspection.
  • 9 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

15 Nov 2012
21 CFR 111.70(b)(1)

Specifications - component identity

Cited by Kathleen S Tormey

15 Nov 2012
21 CFR 111.70(b)(2)

Specifications-component purity, strength, composition

Cited by Kathleen S Tormey

15 Nov 2012
21 CFR 111.70(e)

Specifications - identity, purity, strength, composition

Cited by Kathleen S Tormey

15 Nov 2012
21 CFR 111.75(a)(1)(i)

Component - verify identity, dietary ingredient

Cited by Kathleen S Tormey

15 Nov 2012
21 CFR 111.75(a)(2)(ii)(A)

Component - qualify supplier

Cited by Kathleen S Tormey

Inspected site

ILInnovita, LLCOgden, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 111.610(a)Cited across public-safe Form 483 observations1x
21 CFR 111.70(b)(1)Cited across public-safe Form 483 observations1x
21 CFR 111.70(b)(2)Cited across public-safe Form 483 observations1x
21 CFR 111.70(e)Cited across public-safe Form 483 observations1x
21 CFR 111.75(a)(1)(i)Cited across public-safe Form 483 observations1x
21 CFR 111.75(a)(2)(ii)(A)Cited across public-safe Form 483 observations1x
21 CFR 111.75(c)Cited across public-safe Form 483 observations1x
21 CFR 111.75(c)(1)Cited across public-safe Form 483 observations1x
21 CFR 111.83(a)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 9 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere